Plain-English translation of NCT05370079 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are trying to develop better diagnostic tools for two rare conditions: autoimmune encephalitis and paraneoplastic neurological syndromes. To do this, they're collecting blood samples from people who have other neurological diseases or cancers, so they can compare the samples and identify unique genetic markers that help distinguish these rare conditions from more common ones.
These rare brain conditions are extremely difficult to diagnose because they can look similar to other neurological diseases. By studying blood samples from people with known conditions, researchers hope to discover specific genetic signatures that will make diagnosis faster and more accurate for future patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would donate a blood sample that researchers will analyze to look for genetic markers. This is a diagnostic study, not a treatment trial, so you won't receive any medication or ongoing interventions. The study involves a single visit where blood is collected—similar to a routine lab test.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
France
Sponsor
Hospices Civils de Lyon
Enrollment target
~350 participants
Started
August 2023
Primary completion
August 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jerome Honnorat, Pr
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.